OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Deng on the Effects of MSH6 on PARP Inhibitor Sensitivity in Ovarian Cancer

July 10th 2025

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Dr Ganti on the Importance of Molecular Testing in NSCLC

July 10th 2025

Apar Kishor Ganti, MD, discusses the importance of molecular testing in NSCLC and the profiling capabilities of the Oncomine DX Express Test.

Dr Pan on the Novel Therapy Anito-Cel in Relapsed/Refractory Myeloma

July 10th 2025

Darren Pan, MD, highlights the novelty of anito-cel in relapsed/refractory multiple myeloma, including the difference in safety profile vs cilta-cel.

Dr Puri on Future Research Directions in SCLC

July 9th 2025

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

Dr Hayne on the Implications of the ANZUP 1301 Trial of Mitomycin Plus BCG in NMIBC

July 9th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.

Dr Chehrazi-Raffle on Tivozanib With/Without Nivolumab in Metastatic RCC

July 9th 2025

Alexander Chehrazi-Raffle, MD, discusses findings from an exploratory analysis of the TiNivo-2 trial of tivozanib with/without nivolumab in metastatic RCC.

Dr Chari on the Evolving Determination of Transplant Eligibility in Multiple Myeloma

July 9th 2025

Ajai Chari, MD, expands on the evolving debate surrounding transplant eligibility determination in newly diagnosed multiple myeloma.

Dr Morgans on the Influence of HRQOL Data on the Use of Darolutamide Plus ADT in mHSPC

July 9th 2025

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

Dr Vogel on the European Commission’s Marketing Authorization of Zanidatamab for HER2+ Biliary Tract Cancer

July 9th 2025

Dr Arora on A Retrospective Analysis of Temporal Trends to Assess MCL Incidence From 2000-2021

July 9th 2025

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

Dr Voorhees on the Clinical Implications of Cilta-Cel in Relapsed/Refractory Myeloma

July 9th 2025

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Powles on Implications of the CREST Study of Sasanlimab Plus BCG in BCG-Naive NMIBC

July 8th 2025

Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.

Dr Haas on the Safety Profile of Adjuvant Pembrolizumab in Clear Cell RCC

July 8th 2025

Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Dr Mehnert on the Efficacy of Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab in Unresectable Melanoma

July 8th 2025

Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.

Dr Lotan on Guideline-Supported Treatment Decision-Making for NMIBC

July 7th 2025

Yair Lotan, MD, discusses guideline-supported treatment avenues for patients with BCG-unresponsive NMIBC.

Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC

July 7th 2025

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum

July 7th 2025

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

Dr Olawaiye on Phase 2 Data With Relacorilant and Nab-Paclitaxel in Ovarian Cancer

July 7th 2025

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

Dr Finn on Adding Tiragolumab to Atezolizumab and Bevacizumab in Locally Advanced or Metastatic HCC

July 5th 2025

Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites

July 5th 2025

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.